
BTTX
Healthcare · Biotechnology · $5,452 market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 30-day revisions 1 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2023 | Before the open | -0.19 | -0.15 | +21.1% |
| Aug 9, 2023 | After the close | -0.31 | -0.24 | +22.6% |
| May 11, 2023 | Before the open | -0.74 | -0.39 | +47.3% |
| Mar 30, 2023 | Before the open | -0.51 | -0.37 | +27.5% |
| Nov 14, 2022 | After the close | -0.48 | -0.48 | 0.0% |
| Aug 11, 2022 | Before the open | -0.45 | -0.42 | +6.7% |
| May 13, 2022 | Before the open | -0.38 | -0.41 | -7.9% |
| Mar 28, 2022 | Before the open | -0.46 | -0.71 | -54.3% |
| Nov 23, 2021 | Before the open | -1.66 | -0.03 | +98.2% |
| Aug 20, 2021 | After the close | — | -1.73 | — |
| May 24, 2021 | After the close | 0.00 | -0.01 | — |
| Mar 31, 2021 | After the close | 0.00 | -1.10 | — |
| Oct 16, 2020 | Time not confirmed | 0.00 | -0.00 |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other…
| — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.29 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.36 | — |